1. Body mass index (BMI) ≥ 28.0 kg/m2;

2. The results of PSG meet the diagnosis criteria of OSA and with an AHI ≥15 at screening;

3. Participants must not have used PAP for at least 4 weeks prior to screening and not use PAP during the study;

4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

1. History of endocrine disorders which have significant impact on body weight;

2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state/coma;

3. HbA1c ≥6.5% at screening;

4. Fasting blood glucose ≥7.0 mmol/L or 2-hour blood glucose ≥11.1 mmol/L after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol/L but <7.0 mmol/L require OGTT;

5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas ≥50%;

6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;

7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;

8. Change of body weight >5% within 3 months prior to screening (self-reported);

9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);

10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.